title: From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.
abstract: The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future. The key drivers include: growing patient demand for timely access to promising therapies, emerging science leading to fragmentation of treatment populations, rising payer influence on product accessibility, and pressure on pharma/investors to ensure sustainability of drug development. We also discuss a number of environmental changes that will enable an adaptive paradigm. A life-span approach to bringing innovation to patients is expected to help address the perceived access vs. evidence trade-off, help de-risk drug development, and lead to better outcomes for patients.
authors: European Medicines Agency (EMA), London, UK.
authors: H-G
authors: HG
authors: Eichler
authors: L G
authors: LG
authors: Baird
authors: R
authors: R
authors: Barker
authors: B
authors: B
authors: Bloechl-Daum
authors: F
authors: F
authors: Børlum-Kristensen
authors: J
authors: J
authors: Brown
authors: R
authors: R
authors: Chua
authors: S
authors: S
authors: Del Signore
authors: U
authors: U
authors: Dugan
authors: J
authors: J
authors: Ferguson
authors: S
authors: S
authors: Garner
authors: W
authors: W
authors: Goettsch
authors: J
authors: J
authors: Haigh
authors: P
authors: P
authors: Honig
authors: A
authors: A
authors: Hoos
authors: P
authors: P
authors: Huckle
authors: T
authors: T
authors: Kondo
authors: Y
authors: Y
authors: Le Cam
authors: H
authors: H
authors: Leufkens
authors: R
authors: R
authors: Lim
authors: C
authors: C
authors: Longson
authors: M
authors: M
authors: Lumpkin
authors: J
authors: J
authors: Maraganore
authors: B
authors: B
authors: O'Rourke
authors: K
authors: K
authors: Oye
authors: E
authors: E
authors: Pezalla
authors: F
authors: F
authors: Pignatti
authors: J
authors: J
authors: Raine
authors: G
authors: G
authors: Rasi
authors: T
authors: T
authors: Salmonson
authors: D
authors: D
authors: Samaha
authors: S
authors: S
authors: Schneeweiss
authors: P D
authors: PD
authors: Siviero
authors: M
authors: M
authors: Skinner
authors: J R
authors: JR
authors: Teagarden
authors: T
authors: T
authors: Tominaga
authors: M R
authors: MR
authors: Trusheim
authors: S
authors: S
authors: Tunis
authors: T F
authors: TF
authors: Unger
authors: S
authors: S
authors: Vamvakas
authors: G
authors: G
authors: Hirsch
mesh_terms: D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000379:methods*; D055808:Drug Discovery / Q000331:legislation & jurisprudence*; D006801:Humans; D008004:Licensure